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Febrile seizure is common disorder in childhood, with a prevalence of 
2% to 5%. There are many drugs for treatment of this disease; however, 
the most common prescribed medication in Iran is phenobarbital that 
is cheap, but it has many side effects. We aimed to compare the cost-
effectiveness of topiramate versus phenobarbital in patients with 
febrile seizure in the south of Iran.
Materials & Methods
This econometric cost-effectiveness and cost-utility study were 
conducted on 91 patients with febrile seizure to assess two strategies 
of oral drug therapy including phenobarbital and topiramate in 2016-
2017. Of all, 51 patients were treated with phenobarbital and 40 patients 
received topiramate. We followed up the patients for six months, using 
a randomized and single-blinded approach. A decision tree model was 
used. The outcomes of the model included febrile seizure and utility. 
The study was conducted from the perspective of the community; 
therefore, direct and indirect costs were included in the study. Excel 
and Tree Age software (2011) were used to analyze the results.
Results
Topiramate was cheaper and more effective than phenobarbital. In 
patients in the phenobarbital and topiramate groups, the mean costs 
were $740 and $674 per PPP, utility scores were 0.72 and 0.82, and 
febrile seizure without side effects were 0.3 and 0.6, respectively. 
Moreover, one-way sensitivity analysis confirmed the robustness of 
the results of the study.
Conclusion
Topiramate in patients with febrile seizure is a fully cost-effective and 
cost-efficient strategy suggested as a better alternative for children 
with febrile seizure.
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Introduction
In childhood, febrile seizures are the most prevalent 
seizures (1). The prevalence of this disease in most 
parts of the world is 2% to 5%, and 1% to 6% 
of people with epilepsy have a history of febrile 
seizure (2). The disease is generally of two types, 
simple and complex. About 65% to 90% of the 
febrile seizures are simple (3). If one has a family 
history of febrile seizure, he/she will be 31% more 
likely than others to develop the disease, and family 
history seems to have a significant effect on febrile 
seizure (4). The prevalence of febrile seizure (in 
particular, complex febrile seizure) has increased 
over the past decade (5). 
No treatment is required for febrile seizure 
occurring once or twice, but it needs medications 
if repeated. Febrile seizure that lasts for more than 
five minutes requires treatment and medications, 
but in 30% of cases, the drugs have probable side 
effects (6). The occurrence of this disease can have 
a great impact on the parents and cause anxiety and 
tensions in the family (7). The pathophysiology of 
this disease is unknown and both genetic factors 
and environment can affect the disease (8). The 
prognosis of this disease is good and in some 
cases, it may progress to epilepsy (9, 10). The 
disease requires prolonged therapeutic courses 
and the treatment of patients with febrile seizure 
and epilepsy usually lasts for a long period. In 
addition, the drugs used for the treatment can 
cause many side effects and these side effects have 
a great impact on the patient’s quality of life, and 
the patient has to incur lots of costs to treat these 
side effects (11). Therefore, it seems reasonable 
to avoid the repetition of febrile seizure as far as 
possible using safe methods (12).
Many drugs are prescribed for patients with febrile 
seizure and epilepsy, but because of the differences 
in the costs, effectiveness, and side effects, there 
are controversies over selecting the best drug to be 
prescribed (13). Phenobarbital is one of the drugs 
commonly prescribed in Iran. Phenobarbital is a 
drug used orally and intravenously to treat patients 
with this disease (14). Topiramate is another 
drug widely used in the world to treat local and 
general seizure (15). However, both topiramate 
and phenobarbital have side effects. Side effects 
of phenobarbital include behavioral problems, 
sleepiness, acne, and cognitive problems (16), and 
those of topiramate include weakness, sleepiness, 
lack of speech, depression, depression problems, 
hallucinations, imbalance, dizziness, numbness, 
headache, diarrhea, nausea, anorexia, speech 
impairment, sweating, kidney stones, infection, 
and fever (17-20). It seems reasonable to prevent 
the recurrence of febrile seizure, as far as possible, 
using safe methods. Nonetheless, there is no 
therapeutic regimen accepted by all experts. In 
addition, there are controversies over the efficacy 
and side effects of these drugs, and there are 
uncertainties over choosing the best drug to be 
prescribed by physicians (21).
Policymakers will never have enough money to 
do whatever they want, it is not enough to know 
all the existing interventions to solve a health 
problem; hence, they also need to be aware of the 
costs of interventions (22). Since there are different 
methods and medications for treating patients with 
this disease, it is very important to choose a method 
that is both more effective and less costly (23). 
Therefore, we aimed to assess the cost-effectiveness 
of phenobarbital and topiramate drugs in patients 
with febrile seizure in the south of Iran to identify 
the most cost-effective drug for patients with the 
disease.
111
Cost-Effectiveness Analysis of Topiramate versus Phenobarbital in the Treatment of Children with Febrile Seizure
Iran J Child Neurol. Autumn 2019 Vol.13 No. 4
Materials & Methods
Overview
This cost-effectiveness study was conducted on 91 
patients with febrile seizure referred to Nemazee & 
Dastgheib hospitals, and Imam Reza Clinic, Shiraz 
University of Medical Sciences, Shiraz, Iran, to 
assess two strategies of oral drug therapy including 
phenobarbital and topiramate in 2016-2017. Of 
all, 51 patients were treated with phenobarbital 
and 40 patients received topiramate. In order to 
collect the required data, using a randomized 
and single-blinded approach, we followed up the 
patients for six months. A decision tree model 
was used to estimate the economic and clinical 
outcomes. Data on costs were collected from the 
community viewpoint, and the lack of recurrence 
of febrile seizure and quality-adjusted life year 
(QALY) were set as the effectiveness outcomes. 
We used a form to collect data on costs and 
effectiveness; furthermore, EQ-5D questionnaire 
was used to estimate the utility scores. The results 
were presented in form of the Incremental Cost-
Effectiveness Ratio (ICER). Moreover, one-way 
sensitivity analysis was performed to measure the 
uncertainty effects of the parameters in the model. 
TreeAge Pro 2011 and Excel 2016 software were 
used for the analysis of the collected data.
This Manuscript is extracted from MSc thesis that 
was funded and approved by Shiraz University 
of Medical Sciences with the ID number of 95-
01-07-12635. In addition, it was approved by the 
Ethics Committee of Shiraz University of Medical 
Sciences with the ID number of IR.SUMS.
REC.1396.S31. The informed consent was taken 
from all patients.
Type of the study
This study was an economic evaluation of the cost-
effectiveness and cost-utility analysis, conducted 
as a single-blinded randomized controlled trial 
(RCT) in 2016-2017. Children under five years 
of age with febrile seizure in the south of the 
country were followed up for six months. The 
participants of the study were the patients with 
febrile seizure under five years of age referred 
to hospitals and clinics for the treatment of the 
disease by Mar 2017 and received one of the two 
drugs of topiramate or phenobarbital. The mean 
dose of topiramate and phenobarbital were 5-7 and 
5 mg/kg/d in 2 divided doses; respectively. The 
number of patients receiving phenobarbital and 
topiramate was 51 and 40 persons, respectively. 
Our studied subjects included children who had 
more than two cases of complex febrile seizure 
or simple febrile seizure diagnosed by a pediatric 
neurologist. Considering the research objectives 
and community size, we used the census method 
to select the samples. Since topiramate was not 
familiar for these patients in Iran and was more 
commonly prescribed for patients with epilepsy, 
first, the drug was introduced to the parents of the 
patients and written consent forms were obtained 
from those who were willing to participate in the 
study. If not willing to participate in the study, they 
were allowed to withdraw from the study. The 
samples were divided into two groups, A and B. 
Then, a type of these drugs was prescribed for each 
group of patients. The patients were selected quite 
randomly through randomized block permutation 
design. The researcher made telephone calls to 
the parents of the patients, collected data, and 
completed the cost and effectiveness checklist for 
each drug.
Inclusion and Exclusion Criteria
The inclusion criteria were as follows: Age 6 
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months to 60 months, no history of afebrile 
seizure without fever, three times or more simple 
febrile seizure or complex seizure; lack of Central 
Nervous System (CNS) infection and without 
Electrolyte Imbalance. The exclusion criteria were 
change in the diagnosis of the disorder; resulting in 
continuation of another drug for the child; quitting 
treatment due to the occurrence of drug side effect.
Clinical inputs
To compare the efficacy of the drugs, we used 
the following clinical outcomes: lack of recurrent 
febrile seizure and utility. They were investigated 
through administering the drugs and following up 
the patients for six months. To determine the amount 
of success and failure of each drug in controlling 
the febrile seizure, the number of patients with 
febrile seizure was divided by the total number 
of patients in each group. Moreover, utility scores 
were obtained using EQ-5D questionnaire and 
patient interviews.
Treatment Costs
Data on direct medical costs were collected from 
outpatient medical records, as well as self-reports 
by the experts in the field. Data on direct non-
medical costs and indirect costs were collected 
based on self-reports by the patients through face-
to-face interviews or telephone calls.
The costs were calculated based on the tariffs in 
2017 and converted to the international dollar 
(purchasing power parity) with an exchange rate 
of 1 dollar = 12032 Rials (24).
Model structure
Figure 1 shows the schematic diagram of decision 
tree model for taking phenobarbital versus 
topiramate.
Using decision tree model and TreeAge software, 
the two clinical options along with their cost of 
treatment, effectiveness, and complications of 
the disease were analyzed. This model assessed 
the recurrence of febrile seizure and utility in 
two groups of patients taking phenobarbital and 
topiramate. For each therapeutic strategy, the 
success and failure of the drugs and their side 
effects were plotted to choose the best treatment 
strategy.
Cost-effectiveness analysis: The model was 
designed in the Tree-age software and the extracted 
data were entered into the model; then, the costs, 
effectiveness, cost-effectiveness, and cost-utility 
were calculated for the two drugs and their ICER 







One-way sensitivity analysis was conducted 
to examine the effects of the uncertainty of the 
parameters on the results of the model. There was 
an attempt to modify the key parameters of the 
model, including the effectiveness and costs per 
drug, and the results are presented in the form of a 
tornado diagram. Because of the lack of a certain 
cost-effectiveness threshold in Iran, as the WHO 
has recommended for developing countries, the 
threshold for each QALY is one to three times 
more than the per capita gross domestic product 
(GDP); according to the Iranian Food and Drug 
Administration, it was about 113 million Rials 
in 2017; thus, its three-fold amount is about 339 
million Rials.
Results
Overall, 91 patients less than five years of age 
with febrile seizure were enrolled. Table 1 presents 
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the descriptive results including the data on sex, 
education, occupation status, residence, and 
income, history of febrile seizure, type of febrile 
seizure, and type of drug used.
As shown in Table 2, in both phenobarbital and 
topiramate groups, the highest amount of cost was 
related to direct medical costs with mean values 
of $322.59 and $314.38 per pp, respectively, and 
the lowest amount of cost was related to indirect 
costs, with mean values of $283.32 and $257.23 
per PPP, respectively. However, the mean total cost 
of treatment with phenobarbital ($739.3 per pp) 
was more than that of treatment with topiramate 
($674 per PPP).
As presented in Figures 1, 2 and Table 3, the results 
of cost-effectiveness analysis and cost-utility 
analysis showed that the calculated effectiveness 
of phenobarbital and topiramate, without the 
expected side effects, was 0.3 and 0.63 (with two 
decimal places), respectively; also, the scores of 
quality of life were 0.72 and 0.82, and the expected 
costs were $740 and $642, respectively. Therefore, 
topiramate had a lower cost, was more effective, 
and had a better level of utility than phenobarbital. 
Thus, it is more preferable than phenobarbital. 
Table 3 presents the findings on cost, effectiveness, 
incremental cost, incremental effectiveness, 
incremental cost-effectiveness ratio (ICER), as 
well as the dominance of drugs over each other in 
the two groups of patients with febrile seizure. As 
compared with topiramate, phenobarbital caused 
more febrile seizure, had lower effectiveness, 
provided a lower quality of life score, and imposed 
additional costs on the patient. Thus, topiramate 
had the lowest cost, the highest expected utility, the 
highest level of effectiveness, with no recurrence 
of the expected febrile seizure within a six-month 
period of follow up.
Uncertainty analysis
The effects of uncertainty were studied using one-
way sensitivity analysis and the values of each 
variable changed by 20% plotted in the form of a 
tornado diagram.
Figure 3 presents the results of one-way sensitivity 
analysis in the form of a tornado diagram. Changes 
in many parameters did not have much effect on 
the results of the study. However, incremental 
cost-effectiveness ratio had the highest level of 
sensitivity to the cost of phenobarbital in patients 
with complications and had the lowest level of 
sensitivity to the likelihood of treatment failure 
of topiramate in patients without complications. 
In fact, the price of phenobarbital in patients 
with complications of the disease was a decisive 
parameter in the ICER.
The results of the tornado diagram indicate that 
incremental cost-effectiveness ratio had the highest 
level of sensitivity to the utility of topiramate and 
had the lowest level of sensitivity to the utility 
of the phenobarbital. In fact, the likelihood of 
the effectiveness of topiramate was the essential 
parameter in the ICER (Figure 4).
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Figure 1. Cost-Effectiveness analysis of the use of phenobarbital and topiramate for treating patients less 
than five years of age with febrile seizure 
 
 









Figure 2. Cost-Utility analysis of the use of phenobarbital and topiramate for treating patients less than 
five years of age with febrile seizure 
 
 
Figure 2. Cost-Utility analysis of the use of phenobarbital and topiramate for treating patients less than five years of age with febrile seizure
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Figure 3. Tornado diagram of cost-effectiveness for patients with febrile seizure treated with 

























Figure 4. Tornado diagram of cost-utility for patients with febrile seizure treated with phenobarbital and topiramate
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Table 1. Relative and absolute frequency of demographic characteristics of children less than five years of age with febrile seizure in 
2016-2017
Variable Type Number Percentage
Province of residence
Fars 80 87.9







Type of febrile seizure
Simple 51 57.1
Complex 38 42.9








Family history of febrile seizure
Yes 33 36.2
No 58 63.8
Type of drug used
Topiramate 40 43.9
Phenobarbital 51 56.1
Recurrence rate of FC in two groups
Yes 22 24.2
No 69 75.8











Medication 20.09 2.9 13 44.88 7 .30
Visits to the doctor 93.1 11.55 54 80.9 11 46
Laboratory tests and Diagnostic 
services 
193.11 23.98 100 188.6 25.9 109
Hospitalization 16.29 2.3 10 0 0 0
Total 322.59 41.73 73 314.38 44 75
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Direct non-medical cost
Transportation 145.73 20.4 91 128.61 20.01 64
Accommodation 82.55 11.55 51 77.16 12.01 50
Meals 55.03 7.7 30 51.44 8 34
Total 283.32 39.65 66 257.23 40.03 62
Indirect Costs 133 18.61 83 103.05 16.04 54
Total 739.3 100 448 674 100 421
Table 3. Results of cost-effectiveness and cost-utility analysis of the use of phenobarbital and topiramate for treating patients with 
febrile seizure












Topiramate 673 0.82 0.64 0 0 0 No need to 
calculate 
ICER




Phonobarbital 740 0.72 0.3 66.82 -0.32 -0.11 Dominated
Discussion
The aim of this study was to evaluate the cost-
effectiveness of phenobarbital and topiramate 
drugs in patients with febrile seizure. Phenobarbital 
is commonly prescribed in Iran for children with 
febrile seizure, but in our county, topiramate is not 
prescribed for children with febrile seizure and is 
only prescribed for epileptic patients. However, the 
pilot administration of topiramate for children with 
febrile seizure has recently been started. The aim 
of this study was to examine the cost-effectiveness 
of these two drugs in order to choose the best 
treatment.
Since no specific study has been conducted on 
febrile seizure so far, we have compared our 
findings with the results of the studies conducted 
on patients with epilepsy, which is a long-term, 
progressive, and persistent type of febrile seizure. 
Most drugs used for patients with epilepsy are 
similar to those used for treating febrile seizure 
(25).
In comparison with phenobarbital, topiramate was 
a better option in terms of both cost-effectiveness 
and cost-utility. As to the lack of recurrence 
of febrile seizure in both groups, the results of 
ICER showed that among treatment strategies in 
the country, topiramate was a superior and cost-
effective option because of its higher efficacy and 
lower costs than phenobarbital. The results of this 
study are consistent with those of a study (26) 
suggesting topiramate was a cost-effective drug.
Moreover, as to the utility outcome in both groups, 
the results of ICER showed that among treatment 
strategies in the country, topiramate was superior 
in terms of utility and had a lower cost; thus, it was 
more cost-effective than phenobarbital. The results 
of this study are consistent with a study (27) that 
reported topiramate as a drug with a high level 
of cost-utility. Nevertheless, the results of this 
study were not consistent with another study (28), 
showing that topiramate is not a drug with a higher 
level of cost-utility.
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Furthermore, the results of one-way sensitivity 
analysis showed that the incremental cost-
effectiveness ratio had the highest level of 
sensitivity to the “utility of patients who consumed 
topiramate”, and incremental cost-effectiveness 
ratio had the highest level of sensitivity to “the cost 
spent by patients who consumed phenobarbital”. 
In both cases, the ICER value was negative; it is 
possible to make definite conclusions about the 
results of the study. Therefore, sensitivity analysis 
did not change the status of topiramate as the most 
effective drug; it is a sign of the robustness of the 
results of the study. Therefore, the results of the 
present study are consistent with other findings 
(26, 27).
The results of this study showed that when the 
outcomes of the econometric evaluation are utility 
and the lack of recurrent febrile seizure in children 
with the disease, topiramate drug is more cost-
effective than the phenobarbital and it is more 
cost-effective, favorable, and the dominant option 
because phenobarbital has a higher expected 
cost and a lower efficacy and lower utility than 
topiramate.
Among the strengths of this study, we can mention 
the followings: inclusion of all costs, including 
direct medical and non-medical costs, as well as 
indirect costs in the model, and the use of regional 
data on costs and effectiveness collected from the 
self-reports of the patients.
Limitations
The study had some limitations. The number 
of patients in this study was small. Conducting 
the study over a longer period could help to 
show the relationships better. Of course, there 
was no problem in finding the patients receiving 
phenobarbital because it is a common drug that 
physicians routinely prescribe for the patients, but 
we had problem finding patients and obtaining 
their parents’ consent to receive topiramate over 
the first two months and even some patients quitted 
the study (this issue was also investigated and 
they quitted the study not because of the drug side 
effects, but because in their viewpoint topiramate 
was not a common drug for treating febrile seizure 
and they had some concerns about this issue). 
Moreover, one of the limitations in this study is 
that the types of complex FC (focal, recurrent or 
prolonged) are not mentioned in two groups, and 
may effect on recurrence rate.    
In addition, topiramate was the most effective 
and superior option for treating the patients, it is 
necessary to generalize the results of this study 
to other settings; for instance, it is necessary 
to consider and assess the epidemiology of the 
disease and demographic structure, availability of 
the resources, costs, evaluation of the outcomes by 
individuals, threshold, and use of various indicators 
of effectiveness in various studies that may affect 
the outcomes of this study. Since the samples in the 
present study were mainly from the south of the 
country, we should be cautious in generalizing the 
results to other communities.
In conclusion, topiramate in children under five 
years of age with febrile seizure is a superior 
strategy with high-cost effectiveness and can be 
considered as a high priority drug, as compared 
with phenobarbital. Moreover, its use as the first 
line of treatment reduces the time of treatment and 
the cost of drug resistance, as compared with the 
phenobarbital drug. Hence, in order to reduce the 
burden of the disease in the community, topiramate 
should be used as the first line of treatment in 
children under five years of age with febrile seizure.
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